open access

Vol 51, No 2 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-06-01
Submitted: 2020-02-22
Get Citation

No significant risk of hematological malignancy in patients with neurofibromatosis type 1: single center study of children and adults

Agata Marjańska, Jan Styczyński, Agnieszka Jatczak-Gaca, Mariusz Wysocki
DOI: 10.2478/ahp-2020-0019
·
Acta Haematol Pol 2020;51(2):102-107.

open access

Vol 51, No 2 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-06-01
Submitted: 2020-02-22

Abstract

Background/Aim

Neurofibromatosis type 1 (NF1) is characterized by the occurrence of multisystem tumors. The objective of this study was to analyze the demographic and oncological profile of 830 NF1-individuals regarding prevalence, type, and spectrum of malignancy.

Patients and methods

The medical records of patients diagnosed with NF1 with a median age of 22.1 years (range: 0.8–81.6 years) who were followed up for malignancies from 1999 to 2018 were retrospectively reviewed.

Results

The prevalence of malignancy occurring in patients diagnosed with NF1 was 34.8% (289/830). The most common types of neoplasia encompassed tumors strictly associated with NF1, including plexiform neurofibromas (PNF; 200/830; 24.1%) and optic pathway gliomas (91/830; 11%). The prevalence of PNFs-transforming to malignant peripheral nerve sheath tumors (MPNST) was 3.5% (7/200). The prevalence of other tumors was 4.8% (40/830). One patient was diagnosed with acute myeloid leukemia (AML), thus the risk of hematological malignancies among all patients with NF1 was 0.1% (1/830). In the population of patients with malignancies, 43/289 (14.9%) individuals were diagnosed with more than one malignancy.

Conclusions

The odds ratio (OR) of malignancy in a studied cohort of patients with NF1 was 23 ( < 0.001), while the OR of hematological malignancy was 5.1 ( = 0.1) in comparison with the general population.

Abstract

Background/Aim

Neurofibromatosis type 1 (NF1) is characterized by the occurrence of multisystem tumors. The objective of this study was to analyze the demographic and oncological profile of 830 NF1-individuals regarding prevalence, type, and spectrum of malignancy.

Patients and methods

The medical records of patients diagnosed with NF1 with a median age of 22.1 years (range: 0.8–81.6 years) who were followed up for malignancies from 1999 to 2018 were retrospectively reviewed.

Results

The prevalence of malignancy occurring in patients diagnosed with NF1 was 34.8% (289/830). The most common types of neoplasia encompassed tumors strictly associated with NF1, including plexiform neurofibromas (PNF; 200/830; 24.1%) and optic pathway gliomas (91/830; 11%). The prevalence of PNFs-transforming to malignant peripheral nerve sheath tumors (MPNST) was 3.5% (7/200). The prevalence of other tumors was 4.8% (40/830). One patient was diagnosed with acute myeloid leukemia (AML), thus the risk of hematological malignancies among all patients with NF1 was 0.1% (1/830). In the population of patients with malignancies, 43/289 (14.9%) individuals were diagnosed with more than one malignancy.

Conclusions

The odds ratio (OR) of malignancy in a studied cohort of patients with NF1 was 23 ( < 0.001), while the OR of hematological malignancy was 5.1 ( = 0.1) in comparison with the general population.

Get Citation

Keywords

hematological malignancy; neurofibromatosis type 1; phacomatosis; optic pathway glioma; brain tumor; acute myeloid leukemia

About this article
Title

No significant risk of hematological malignancy in patients with neurofibromatosis type 1: single center study of children and adults

Journal

Acta Haematologica Polonica

Issue

Vol 51, No 2 (2020)

Pages

102-107

Published online

2020-06-01

DOI

10.2478/ahp-2020-0019

Bibliographic record

Acta Haematol Pol 2020;51(2):102-107.

Keywords

hematological malignancy
neurofibromatosis type 1
phacomatosis
optic pathway glioma
brain tumor
acute myeloid leukemia

Authors

Agata Marjańska
Jan Styczyński
Agnieszka Jatczak-Gaca
Mariusz Wysocki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl